Aim: Current treatment options for depression have remained unsatisfactory because some patients experience symptoms even after completing multiple antidepressants and more aggressive treatments, besides experiencing side effects and uncertain adherence. Several studies have shown an association between magnesium and depression but have not consistently shown significant results.
Methods: Ninety subjects with moderate or severe major depressive disorder were randomized into a double-blind placebo-controlled trial to receive a treatment of 200 mg of magnesium glycinate or placebo tablets twice daily orally with selective serotonin reuptake inhibitors for the 8 weeks intervention period. Subjects were assessed with the Depression Anxiety Stress Scale 21 items Bangla Version for depression symptoms at baseline, at the end of the 4 weeks, and at the end of the 8 weeks intervention, and to evaluate the appearance of adverse effects.
Results: Supplementation of oral magnesium glycinate for 8 weeks resulted in a significant reduction in Depression Anxiety Stress Scale 21 items score from baseline (P < 0.05) and this reduction was observed from the end of 4 weeks treatment. Also, at the end of 8 weeks, the Depression Anxiety Stress Scale 21 items score was significantly lower than that of the control arm (P = 0.02). No changes were noted in the reporting of adverse effects while on the treatment.
Conclusion: Magnesium glycinate significantly reduces symptoms in moderate to severe depression, works quickly, and is well tolerated; this result is consistent with the literature. The link between changes in the Depression Anxiety Stress Scale 21 items and the severity of depression symptoms supports the idea that magnesium glycinate could be utilized to treat major depressive disorder, a persistent medical problem.
Trial was registered in the ClinicalTrials.gov with the trial ID number NCT04880460.
Keywords: Control; DASS-21; Depression; Intervention; Magnesium; SSRIs
Sarmin Sultana and Md Sayedur Rahman. “Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients: A Randomized, Double-Blind, Placebo-Controlled Trial”. EC Nutrition  18.2 (2023): 35-49.
© 2023 Sarmin Sultana and Md Sayedur Rahman. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by ECronicon is
licensed under a Creative Commons Attribution
4.0 International License
Based on a work at www.ecronicon.org